Erin Longbrake, MD/PhD

Multiple Sclerosis; Neuromyelitis Optica; Autoimmune Diseases of the Nervous System

Genetics, Genomics, Epigenetics; Immunology; Nutrition; Microbiome

• Central vein sign: A diagnostic biomarker in multiple sclerosis (CAVS-MS) study protocol for a prospective multicenter trialOntaneda D, Sati P, Raza P, Kilbane M, Gombos E, Alvarez E, Azevedo C, Calabresi P, Cohen JA, Freeman L, Henry RG, Longbrake EE, Mitra N, Illenberger N, Schindler M, Moreno-Dominguez D, Ramos M, Mowry E, Oh J, Rodrigues P, Chahin S, Kaisey M, Waubant E, Cutter G, Shinohara R, Reich DS, Solomon A, Sicotte NL, Cooperative N. Central vein sign: A diagnostic biomarker in multiple sclerosis (CAVS-MS) study protocol for a prospective multicenter trial. NeuroImage Clinical 2021, 32: 102834. PMID: 34592690, PMCID: PMC8482479, DOI: 10.1016/j.nicl.2021.102834.
• Myelin Oligodendrocyte Glycoprotein–Associated DisordersLongbrake E. Myelin Oligodendrocyte Glycoprotein–Associated Disorders. CONTINUUM Lifelong Learning In Neurology 2022, 28: 1171-1193. PMID: 35938661, PMCID: PMC9523511, DOI: 10.1212/con.0000000000001127.
• Consensus Curriculum for Fellowship Training in Multiple Sclerosis and NeuroimmunologyHua LH, Obeidat AZ, Amezcua L, Cohen JA, Costello K, Dunn J, Gelfand JM, Goldman MD, Hopkins S, Jeffery D, Krieger S, Newsome SD, Shah S, Sicotte NL, Yadav V, Longbrake EE. Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology. Neurology Clinical Practice 2021, 11: 352-357. PMID: 34484933, PMCID: PMC8382436, DOI: 10.1212/cpj.0000000000001040.
• Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activityShinoda K, Li R, Rezk A, Mexhitaj I, Patterson K, Kakara M, Zuroff L, Bennett J, von Büdingen H, Carruthers R, Edwards K, Fallis R, Giacomini P, Greenberg B, Hafler D, Ionete C, Kaunzner U, Lock C, Longbrake E, Pardo G, Piehl F, Weber M, Ziemssen T, Jacobs D, Gelfand J, Cross A, Cameron B, Musch B, Winger R, Jia X, Harp C, Herman A, Bar-Or A. Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2207291120. PMID: 36634138, PMCID: PMC9934304, DOI: 10.1073/pnas.2207291120.
• Prior cycles of anti-CD20 antibodies affect antibody responses after repeated SARS-CoV-2 mRNA vaccinationAsashima H, Kim D, Wang K, Lele N, Buitrago-Pocasangre N, Lutz R, Cruz I, Raddassi K, Ruff W, Racke M, Wilson J, Givens T, Grifoni A, Weiskopf D, Sette A, Kleinstein S, Montgomery R, Shaw A, Li F, Fan R, Hafler D, Tomayko M, Longbrake E. Prior cycles of anti-CD20 antibodies affect antibody responses after repeated SARS-CoV-2 mRNA vaccination. JCI Insight 2023, 8: e168102. PMID: 37606046, PMCID: PMC10543713, DOI: 10.1172/jci.insight.168102.
• Impact of the COVID-19 Pandemic on the Personal Networks and Neurological Outcomes of People With Multiple Sclerosis: Cross-Sectional and Longitudinal Case-Control StudyRiley C, Venkatesh S, Dhand A, Doshi N, Kavak K, Levit E, Perrone C, Weinstock-Guttman B, Longbrake E, De Jager P, Xia Z. Impact of the COVID-19 Pandemic on the Personal Networks and Neurological Outcomes of People With Multiple Sclerosis: Cross-Sectional and Longitudinal Case-Control Study. JMIR Public Health And Surveillance 2024, 10: e45429. PMID: 38319703, PMCID: PMC10879979, DOI: 10.2196/45429.
• Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease managementAlvarez E, Longbrake E, Rammohan K, Stankiewicz J, Hersh C. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management. Multiple Sclerosis And Related Disorders 2023, 79: 105009. PMID: 37783194, DOI: 10.1016/j.msard.2023.105009.
• Anti‐CD20 monoclonal antibody therapy in postpartum women with neurological conditionsAnderson A, Rowles W, Poole S, Balan A, Bevan C, Brandstadter R, Ciplea A, Cooper J, Fabian M, Hale T, Jacobs D, Kakara M, Krysko K, Longbrake E, Marcus J, Repovic P, Riley C, Romeo A, Rutatangwa A, West T, Hellwig K, LaHue S, Bove R. Anti‐CD20 monoclonal antibody therapy in postpartum women with neurological conditions. Annals Of Clinical And Translational Neurology 2023, 10: 2053-2064. PMID: 37675826, PMCID: PMC10647007, DOI: 10.1002/acn3.51893.
• Early Treatment for Multiple SclerosisLongbrake E, Kalincik T. Early Treatment for Multiple Sclerosis. Neurology 2023, 101: 549-550. PMID: 37468283, DOI: 10.1212/wnl.0000000000207754.
• Influence of menstrual cycle and hormonal contraceptive use on MS symptom fluctuations: A pilot studyTaylor H, Alhasan S, Saleem M, Poole S, Jiang F, Longbrake E, Bove R. Influence of menstrual cycle and hormonal contraceptive use on MS symptom fluctuations: A pilot study. Multiple Sclerosis And Related Disorders 2023, 77: 104864. PMID: 37480738, DOI: 10.1016/j.msard.2023.104864.
• Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine ProtectionKim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection. Small Methods 2023, 7: e2300594. PMID: 37312418, PMCID: PMC10592458, DOI: 10.1002/smtd.202300594.
• MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicityYandamuri S, Filipek B, Obaid A, Lele N, Thurman J, Makhani N, Nowak R, Guo Y, Lucchinetti C, Flanagan E, Longbrake E, O'Connor K. MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity. JCI Insight 2023, 8: e165373. PMID: 37097758, PMCID: PMC10393237, DOI: 10.1172/jci.insight.165373.
• Impact of the COVID-19 Pandemic on Personal Networks and Neurological Outcomes of People with Multiple Sclerosis (P12-3.001)Venkatesh S, Riley C, Dhand A, Doshi N, Kavak K, Levit E, Perrone C, Weinstock-Guttman B, Longbrake E, De Jager P, Xia Z. Impact of the COVID-19 Pandemic on Personal Networks and Neurological Outcomes of People with Multiple Sclerosis (P12-3.001). Neurology 2023, 100 DOI: 10.1212/wnl.0000000000203369.
• Time for the Next Step in Clinical Trial Evolution?Longbrake E. Time for the Next Step in Clinical Trial Evolution? Annals Of Neurology 2023, 93: 1051-1052. PMID: 36976460, DOI: 10.1002/ana.26655.
• Future of Neurology & Technology: Neuroimaging Made Accessible Using Low-Field, Portable MRIParasuram N, Crawford A, Mazurek M, Chavva I, Beekman R, Gilmore E, Petersen N, Payabvash S, Sze G, Eugenio Iglesias J, Omay S, Matouk C, Longbrake E, de Havenon A, Schiff S, Rosen M, Kimberly W, Sheth K. Future of Neurology & Technology: Neuroimaging Made Accessible Using Low-Field, Portable MRI. Neurology 2023, 100: 1067-1071. PMID: 36720639, PMCID: PMC10259275, DOI: 10.1212/wnl.0000000000207074.
• Anti-CRMP5 optic neuropathy associated with oral squamous cell carcinomaNulton C, Longbrake E, Alkawadri R, Alkawadri C. Anti-CRMP5 optic neuropathy associated with oral squamous cell carcinoma. Neuroimmunology Reports 2023, 3: 100170. DOI: 10.1016/j.nerep.2023.100170.
• High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple SclerosisFreeman L, Longbrake E, Coyle P, Hendin B, Vollmer T. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis. CNS Drugs 2022, 36: 1285-1299. PMID: 36350491, PMCID: PMC9645316, DOI: 10.1007/s40263-022-00965-7.
• Infection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic diseasePeters J, Longbrake E. Infection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic disease. Multiple Sclerosis And Related Disorders 2022, 68: 104400. PMID: 36544307, PMCID: PMC10075342, DOI: 10.1016/j.msard.2022.104400.
• Impaired TIGIT expression on B cells drives circulating follicular helper T cell expansion in multiple sclerosisAsashima H, Axisa PP, Pham THG, Longbrake EE, Ruff WE, Lele N, Cohen I, Raddassi K, Sumida TS, Hafler DA. Impaired TIGIT expression on B cells drives circulating follicular helper T cell expansion in multiple sclerosis. Journal Of Clinical Investigation 2022, 132: e156254. PMID: 36250467, PMCID: PMC9566906, DOI: 10.1172/jci156254.
• Impact of resilience, social support, and personality traits in patients with neuroinflammatory diseases during the COVID-19 pandemicJakimovski D, Kavak KS, Longbrake EE, Levit E, Perrone CM, Bar-Or A, Benedict RH, Riley CS, De Jager PL, Venkatesh S, Walker ELS, Xia Z, Weinstock-Guttman B, Collaborative M. Impact of resilience, social support, and personality traits in patients with neuroinflammatory diseases during the COVID-19 pandemic. Multiple Sclerosis And Related Disorders 2022, 68: 104235. PMID: 36283322, PMCID: PMC9548342, DOI: 10.1016/j.msard.2022.104235.
• Curriculum Innovations: Virtual Didactics as a Tool for Harmonizing Education About Rare Topics in NeuroimmunologyPeters J, Cohen J, Corboy J, Hopkins S, Hua L, Kakara M, McFaul D, Obeidat A, Yadav V, Longbrake E. Curriculum Innovations: Virtual Didactics as a Tool for Harmonizing Education About Rare Topics in Neuroimmunology. Neurology Education 2022, 1: e200008. DOI: 10.1212/ne9.0000000000200008.
• Toward Precision Phenotyping of Multiple SclerosisPitt D, Lo CH, Gauthier SA, Hickman RA, Longbrake E, Airas LM, Mao-Draayer Y, Riley C, De Jager PL, Wesley S, Boster A, Topalli I, Bagnato F, Mansoor M, Stuve O, Kister I, Pelletier D, Stathopoulos P, Dutta R, Lincoln MR. Toward Precision Phenotyping of Multiple Sclerosis. Neurology Neuroimmunology & Neuroinflammation 2022, 9: e200025. PMID: 36041861, PMCID: PMC9427000, DOI: 10.1212/nxi.0000000000200025.
• The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndromeLongbrake EE, Hua LH, Mowry EM, Gauthier SA, Alvarez E, Cross AH, Pei J, Priest J, Raposo C, Hafler DA, Winger RC. The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome. Multiple Sclerosis And Related Disorders 2022, 68: 104143. PMID: 36031693, PMCID: PMC9772048, DOI: 10.1016/j.msard.2022.104143.
• Effect of GBCA Use on Detection and Diagnostic Performance of the Central Vein Sign: Evaluation Using a 3-T FLAIR* Sequence in Patients With Suspected Multiple Sclerosis.Daboul L, O'Donnell CM, Cao Q, Amin M, Rodrigues P, Derbyshire J, Azevedo C, Bar-Or A, Caverzasi E, Calabresi P, Cree BAC, Freeman L, Henry RG, Longbrake EE, Nakamura K, Oh J, Papinutto N, Pelletier D, Samudralwar RD, Suthiphosuwan S, Schindler MK, Sotirchos ES, Sicotte NL, Solomon AJ, Shinohara RT, Reich DS, Ontaneda D, Sati P. Effect of GBCA Use on Detection and Diagnostic Performance of the Central Vein Sign: Evaluation Using a 3-T FLAIR* Sequence in Patients With Suspected Multiple Sclerosis. American Journal Of Roentgenology 2022, 220: 115-125. PMID: 35975888, PMCID: PMC10016223, DOI: 10.2214/ajr.22.27731.
• The White Matter Rounds experience: The importance of a multidisciplinary network to accelerate the diagnostic process for adult patients with rare white matter disordersHuang YT, Giacomini PS, Massie R, Venkateswaran S, Trudelle AM, Fadda G, Sharifian-Dorche M, Boudjani H, Poliquin-Lasnier L, Airas L, Saveriano AW, Ziller MG, Miller E, Martinez-Rios C, Wilson N, Davila J, Rush C, Longbrake EE, Longoni G, Macaron G, Bernard G, Tampieri D, Antel J, Brais B, La Piana R. The White Matter Rounds experience: The importance of a multidisciplinary network to accelerate the diagnostic process for adult patients with rare white matter disorders. Frontiers In Neurology 2022, 13: 928493. PMID: 35959404, PMCID: PMC9359417, DOI: 10.3389/fneur.2022.928493.
• Worsening physical functioning in patients with neuroinflammatory disease during the COVID-19 pandemicLevit E, Cohen I, Dahl M, Edwards K, Weinstock-Guttman B, Ishikawa T, Kavak K, Leavitt V, Nelson K, Onomichi K, Bar-Or A, Perrone C, Riley C, Venkatesh S, De Jager PL, Xia Z, Longbrake EE, Collaborative M. Worsening physical functioning in patients with neuroinflammatory disease during the COVID-19 pandemic. Multiple Sclerosis And Related Disorders 2022, 58: 103482. PMID: 35016114, PMCID: PMC8742609, DOI: 10.1016/j.msard.2021.103482.
• Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability DataEpstein S, Xia Z, Lee AJ, Dahl M, Edwards K, Levit E, Longbrake EE, Perrone C, Kavak K, Weinstock-Guttman B, Diallo F, Ricci A, Riley CS, De Jager PL, Farber R, Wesley SF, Collaborative M. Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data. Multiple Sclerosis And Related Disorders 2021, 57: 103433. PMID: 34923427, PMCID: PMC8638239, DOI: 10.1016/j.msard.2021.103433.
• 23Na imaging: Worth its salt for understanding multiple sclerosisLongbrake EE, Hafler DA. 23Na imaging: Worth its salt for understanding multiple sclerosis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2110799118. PMID: 34376559, PMCID: PMC8379906, DOI: 10.1073/pnas.2110799118.
• A New England COVID-19 Registry of Patients With CNS Demyelinating DiseaseMoney KM, Mahatoo A, Samaan S, Anand P, Baber U, Bailey M, Bakshi R, Bouley A, Bower A, Cahill J, Houtchens M, Katz J, Lathi E, Levit E, Longbrake EE, McAdams M, Napoli S, Raibagkar P, Wade P, Sloane JA. A New England COVID-19 Registry of Patients With CNS Demyelinating Disease. Neurology Neuroimmunology & Neuroinflammation 2021, 8: e1046. PMID: 34341094, PMCID: PMC8362350, DOI: 10.1212/nxi.0000000000001046.
• Neuroinflammation Associated With Tumor Necrosis Factor-α Inhibitor ExposureYu AW, Pecsok M, Longbrake EE, Wesley SF. Neuroinflammation Associated With Tumor Necrosis Factor-α Inhibitor Exposure. Neurology Clinical Practice 2021, 11: e488-e496. PMID: 34484946, PMCID: PMC8382406, DOI: 10.1212/cpj.0000000000001014.
• The Role of Immune Checkpoint Therapy in Propagating Neurologic Immune-Related Adverse Events: Inducing or "Unmasking" Autoimmunity?Gardin T, Longbrake EE. The Role of Immune Checkpoint Therapy in Propagating Neurologic Immune-Related Adverse Events: Inducing or "Unmasking" Autoimmunity? Neurology 2021, 96: 733-734. PMID: 33727404, DOI: 10.1212/wnl.0000000000011812.
• MOG-associated encephalitis following SARS-COV-2 infectionPeters J, Alhasan S, Vogels CBF, Grubaugh ND, Farhadian S, Longbrake EE. MOG-associated encephalitis following SARS-COV-2 infection. Multiple Sclerosis And Related Disorders 2021, 50: 102857. PMID: 33647592, PMCID: PMC7900751, DOI: 10.1016/j.msard.2021.102857.
• Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseasesLevin SN, Venkatesh S, Nelson KE, Li Y, Aguerre I, Zhu W, Masown K, Rimmer KT, Diaconu CI, Onomichi KB, Leavitt VM, Levine LL, Strauss‐Farber R, Vargas WS, Banwell B, Bar‐Or A, Berger JR, Goodman AD, Longbrake EE, Oh J, Weinstock‐Guttman B, Thakur KT, Edwards KR, Riley CS, Xia Z, De Jager PL, Collaborative M. Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases. Annals Of Clinical And Translational Neurology 2021, 8: 918-928. PMID: 33616290, PMCID: PMC8013889, DOI: 10.1002/acn3.51314.
• Influence of immunomodulatory drugs on the gut microbiotaCohen I, Ruff WE, Longbrake EE. Influence of immunomodulatory drugs on the gut microbiota. Translational Research 2021, 233: 144-161. PMID: 33515779, PMCID: PMC8184576, DOI: 10.1016/j.trsl.2021.01.009.
• Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunityLongbrake EE, Mao-Draayer Y, Cascione M, Zielinski T, Bame E, Brassat D, Chen C, Kapadia S, Mendoza JP, Miller C, Parks B, Xing D, Robertson D. Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity. Multiple Sclerosis Journal 2020, 27: 883-894. PMID: 32716690, PMCID: PMC8023410, DOI: 10.1177/1352458520937282.
• Therapeutic considerations in a case of progressive encephalomyelitis with rigidity and myoclonusGluck L, Hernandez AL, Wesley SF, Fulbright RK, Longbrake EE, Stathopoulos P. Therapeutic considerations in a case of progressive encephalomyelitis with rigidity and myoclonus. Journal Of The Neurological Sciences 2020, 416: 116993. PMID: 32593886, PMCID: PMC8023411, DOI: 10.1016/j.jns.2020.116993.
• Outcomes and future directions for neuroimmunology/multiple sclerosis fellowship training: Survey of recent traineesHua LH, Obeidat AZ, Longbrake EE. Outcomes and future directions for neuroimmunology/multiple sclerosis fellowship training: Survey of recent trainees. Multiple Sclerosis And Related Disorders 2020, 44: 102296. PMID: 32585616, PMCID: PMC8023409, DOI: 10.1016/j.msard.2020.102296.
• Education Research: Multiple sclerosis and neuroimmunology fellowship training status in the United StatesObeidat AZ, Jassam YN, Hua LH, Cutter G, Ford CC, Halper J, Lisak RP, Sicotte NL, Longbrake EE. Education Research: Multiple sclerosis and neuroimmunology fellowship training status in the United States. Neurology 2020, 94: 10.1212/wnl.0000000000009096. PMID: 32107321, PMCID: PMC9246053, DOI: 10.1212/wnl.0000000000009096.
• Sex effects across the lifespan in women with multiple sclerosisKrysko KM, Graves JS, Dobson R, Altintas A, Amato MP, Bernard J, Bonavita S, Bove R, Cavalla P, Clerico M, Corona T, Doshi A, Fragoso Y, Jacobs D, Jokubaitis V, Landi D, Llamosa G, Longbrake EE, Maillart E, Marta M, Midaglia L, Shah S, Tintore M, van der Walt A, Voskuhl R, Wang Y, Zabad RK, Zeydan B, Houtchens M, Hellwig K. Sex effects across the lifespan in women with multiple sclerosis. Therapeutic Advances In Neurological Disorders 2020, 13: 1756286420936166. PMID: 32655689, PMCID: PMC7331774, DOI: 10.1177/1756286420936166.
• CXCR3+ T cells in multiple sclerosis correlate with reduced diversity of the gut microbiomeChoileáin SN, Kleinewietfeld M, Raddassi K, Hafler DA, Ruff WE, Longbrake EE. CXCR3+ T cells in multiple sclerosis correlate with reduced diversity of the gut microbiome. Journal Of Translational Autoimmunity 2019, 3: 100032. PMID: 32743517, PMCID: PMC7388357, DOI: 10.1016/j.jtauto.2019.100032.
• Siponimod Chips Away at Progressive MSLongbrake EE, Hafler DA. Siponimod Chips Away at Progressive MS. Cell 2019, 179: 1440. PMID: 31951523, PMCID: PMC8023412, DOI: 10.1016/j.cell.2019.11.034.
• CHAPTER 2 Genetics of Multiple SclerosisAbulaban A, Hafler D, Longbrake E. CHAPTER 2 Genetics of Multiple Sclerosis. 2019, 33-54. DOI: 10.1039/9781788016070-00033.
• Effectiveness of alternative dose fingolimod for multiple sclerosisLongbrake EE, Kantor D, Pawate S, Bradshaw MJ, von Geldern G, Chahin S, Cross AH, Parks BJ, Rice M, Khoury SJ, Yamout B, Zeineddine M, Russell-Giller S, Caminero-Rodriguez A, Edwards K, Lathi E, VanderKodde D, Meador W, Berkovich R, Ge L, Bacon TE, Kister I. Effectiveness of alternative dose fingolimod for multiple sclerosis. Neurology Clinical Practice 2018, 8: 102-107. PMID: 29708225, PMCID: PMC5914753, DOI: 10.1212/cpj.0000000000000434.
• A Neurology Clerkship Curriculum Using Video-Based Lectures and Just-in-Time Teaching (JiTT)Dominguez M, DiCapua D, Leydon G, Loomis C, Longbrake EE, Schaefer SM, Becker KP, Detyniecki K, Gottschalk C, Salardini A, Encandela JA, Moeller JJ. A Neurology Clerkship Curriculum Using Video-Based Lectures and Just-in-Time Teaching (JiTT). MedEdPORTAL 2018, 14: 10691. PMID: 30800891, PMCID: PMC6342385, DOI: 10.15766/mep_2374-8265.10691.
• Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSSBaldassari LE, Salter AR, Longbrake EE, Cross AH, Naismith RT. Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS. Multiple Sclerosis Journal 2017, 24: 1347-1355. PMID: 28766993, DOI: 10.1177/1352458517721357.
• Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte countLongbrake EE, Cantoni C, Chahin S, Cignarella F, Cross AH, Piccio L. Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count. Multiple Sclerosis Journal 2017, 24: 728-738. PMID: 28480794, PMCID: PMC5665729, DOI: 10.1177/1352458517707069.
• Quantitative visual tests after poorly recovered optic neuritis due to multiple sclerosisLongbrake EE, Lancia S, Tutlam N, Trinkaus K, Naismith RT. Quantitative visual tests after poorly recovered optic neuritis due to multiple sclerosis. Multiple Sclerosis And Related Disorders 2016, 10: 198-203. PMID: 27919490, PMCID: PMC5392253, DOI: 10.1016/j.msard.2016.10.009.
• The contemporary spectrum of multiple sclerosis misdiagnosisSolomon AJ, Bourdette DN, Cross AH, Applebee A, Skidd PM, Howard DB, Spain RI, Cameron MH, Kim E, Mass MK, Yadav V, Whitham RH, Longbrake EE, Naismith RT, Wu GF, Parks BJ, Wingerchuk DM, Rabin BL, Toledano M, Tobin WO, Kantarci OH, Carter JL, Keegan BM, Weinshenker BG. The contemporary spectrum of multiple sclerosis misdiagnosis. Neurology 2016, 87: 1393-1399. PMID: 27581217, PMCID: PMC5047038, DOI: 10.1212/wnl.0000000000003152.
• Linking Genotype to Clinical Phenotype in Multiple Sclerosis: In Search of the Holy GrailLongbrake EE, Hafler DA. Linking Genotype to Clinical Phenotype in Multiple Sclerosis: In Search of the Holy Grail. JAMA Neurology 2016, 73: 777-8. PMID: 27244583, PMCID: PMC5198230, DOI: 10.1001/jamaneurol.2016.1227.
• An older dog with newer tricks: Predicting efficacy of IFN-β treatment for multiple sclerosisWu GF, Longbrake EE. An older dog with newer tricks: Predicting efficacy of IFN-β treatment for multiple sclerosis. Neurology Neuroimmunology & Neuroinflammation 2016, 3: e218. PMID: 27110589, PMCID: PMC4830190, DOI: 10.1212/nxi.0000000000000218.
• Effect of Multiple Sclerosis Disease-Modifying Therapies on B Cells and Humoral ImmunityLongbrake EE, Cross AH. Effect of Multiple Sclerosis Disease-Modifying Therapies on B Cells and Humoral Immunity. JAMA Neurology 2016, 73: 1-7. PMID: 26720195, DOI: 10.1001/jamaneurol.2015.3977.
• Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practiceLongbrake EE, Cross AH, Salter A. Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice. Multiple Sclerosis Journal - Experimental Translational And Clinical 2016, 2: 2055217316677868. PMID: 28280599, PMCID: PMC5340186, DOI: 10.1177/2055217316677868.
• Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patientsLongbrake E, Ramsbottom M, Cantoni C, Ghezzi L, Cross A, Piccio L. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Multiple Sclerosis Journal 2015, 22: 1061-1070. PMID: 26459150, PMCID: PMC4829494, DOI: 10.1177/1352458515608961.
• Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significanceLongbrake EE, Naismith RT, Parks BJ, Wu GF, Cross AH. Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance. Multiple Sclerosis Journal - Experimental Translational And Clinical 2015, 1: 2055217315596994. PMID: 26550483, PMCID: PMC4636217, DOI: 10.1177/2055217315596994.
• Dimethyl fumarate associated lymphopenia in clinical practiceLongbrake EE, Cross AH. Dimethyl fumarate associated lymphopenia in clinical practice. Multiple Sclerosis Journal 2014, 21: 796-797. PMID: 25432948, PMCID: PMC4426020, DOI: 10.1177/1352458514559299.
• Monoclonal Antibodies as Disease Modifying Therapy in Multiple SclerosisLongbrake EE, Parks BJ, Cross AH. Monoclonal Antibodies as Disease Modifying Therapy in Multiple Sclerosis. Current Neurology And Neuroscience Reports 2013, 13: 390. PMID: 24027005, PMCID: PMC3967547, DOI: 10.1007/s11910-013-0390-z.
• Susac syndrome in a patient with human immunodeficiency virus infectionLongbrake EE, Ances BM, Viets RB, Clifford DB. Susac syndrome in a patient with human immunodeficiency virus infection. Journal Of NeuroVirology 2013, 19: 270-273. PMID: 23690260, PMCID: PMC4582780, DOI: 10.1007/s13365-013-0164-z.
• Deficient CX3CR1 Signaling Promotes Recovery after Mouse Spinal Cord Injury by Limiting the Recruitment and Activation of Ly6Clo/iNOS+ MacrophagesDonnelly DJ, Longbrake EE, Shawler TM, Kigerl KA, Lai W, Tovar CA, Ransohoff RM, Popovich PG. Deficient CX3CR1 Signaling Promotes Recovery after Mouse Spinal Cord Injury by Limiting the Recruitment and Activation of Ly6Clo/iNOS+ Macrophages. Journal Of Neuroscience 2011, 31: 9910-9922. PMID: 21734283, PMCID: PMC3139517, DOI: 10.1523/jneurosci.2114-11.2011.
• Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?Longbrake EE, Racke MK. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? Expert Review Of Neurotherapeutics 2009, 9: 319-321. PMID: 19271940, DOI: 10.1586/14737175.9.3.319.
• Intra‐neural administration of fractalkine attenuates neuropathic pain‐related behaviourHolmes FE, Arnott N, Vanderplank P, Kerr NC, Longbrake EE, Popovich PG, Imai T, Combadière C, Murphy PM, Wynick D. Intra‐neural administration of fractalkine attenuates neuropathic pain‐related behaviour. Journal Of Neurochemistry 2008, 106: 640-649. PMID: 18410510, PMCID: PMC2726982, DOI: 10.1111/j.1471-4159.2008.05419.x.
• Can the immune system be harnessed to repair the CNS?Popovich PG, Longbrake EE. Can the immune system be harnessed to repair the CNS? Nature Reviews Neuroscience 2008, 9: 481-493. PMID: 18490917, DOI: 10.1038/nrn2398.
• Remote activation of microglia and pro-inflammatory cytokines predict the onset and severity of below-level neuropathic pain after spinal cord injury in ratsDetloff MR, Fisher LC, McGaughy V, Longbrake EE, Popovich PG, Basso DM. Remote activation of microglia and pro-inflammatory cytokines predict the onset and severity of below-level neuropathic pain after spinal cord injury in rats. Experimental Neurology 2008, 212: 337-347. PMID: 18511041, PMCID: PMC2600773, DOI: 10.1016/j.expneurol.2008.04.009.
• Characterization and modeling of monocyte‐derived macrophages after spinal cord injuryLongbrake EE, Lai W, Ankeny DP, Popovich PG. Characterization and modeling of monocyte‐derived macrophages after spinal cord injury. Journal Of Neurochemistry 2007, 102: 1083-1094. PMID: 17663750, DOI: 10.1111/j.1471-4159.2007.04617.x.
• REMOTE MICROGLIAL ACTIVATION AND THE PRODUCTION OF PROINFLAMMATORY CYTOKINES PREDICTS THE DEVELOPMENT OF NEUROPATHIC PAIN AFTER SPINAL CORD INJURYDetlof M, Fisher L, McGaughy V, Longbrake E, Popovich P, Basso D. REMOTE MICROGLIAL ACTIVATION AND THE PRODUCTION OF PROINFLAMMATORY CYTOKINES PREDICTS THE DEVELOPMENT OF NEUROPATHIC PAIN AFTER SPINAL CORD INJURY. Journal Of Neurologic Physical Therapy 2006, 30: 202. DOI: 10.1097/01.npt.0000281277.85517.ec.